RxDoctor Payments Data

Donald Henderson, MD

Internal Medicine · Honesdale, PANPI 1689653560

Payments from drug & device makers

$967in general payments, 2019–2025

Across 64 payments — averaging $15.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$152
  • Novartis$136
  • Merck$96
  • Novo Nordisk$84
  • Amarin Pharma, Inc.$78
  • Lilly USA, LLC$50
  • plus $371 from 14 others

What the payments were for

  • Food & beverage$967100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$967 in reported general payments places this provider in the 75th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$213,766
Medicare patients
495
Services billed
28,030

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban172$181,319
OzempicSemaglutide56$86,181
TrulicityDulaglutide49$63,159
JanuviaSitagliptin Phosphate27$33,658
JardianceEmpagliflozin29$26,152
TradjentaLinagliptin31$20,576
MyrbetriqMirabegron29$19,406
XareltoRivaroxaban17$18,946
InvokanaCanagliflozin16$17,859
Breo ElliptaFluticasone/Vilanterol24$9,100
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$5,799
Metoprolol Succinate317$5,378
Potassium Chloride94$5,342
Bromocriptine Mesylate13$5,148
Atorvastatin Calcium448$4,476

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$152$181,319172 claims
Novo NordiskOzempic$84$86,18156 claims
Lilly USA, LLCTrulicity$50$63,15949 claims
Boehringer IngelheimJardiance, Tradjenta, Jentadueto$21$51,12671 claims
Johnson & JohnsonXarelto, Invokana$14$36,80633 claims
MerckJanuvia$96$33,65827 claims
Astellas Pharma US IncMyrbetriq$37$19,40629 claims
GSKBreo Ellipta, Anoro Ellipta$27$14,89937 claims
AbbVieSynthroid$50$1,27227 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Honesdale

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →